The study concluded that key signs of Keratosis follicularis spinulosa decalvans are changes in terminal hair and vellus hairfollicles, which likely start the inflammation and damage to hairfollicles.
A permanent hairloss solution could involve reprogramming hairfollicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hairloss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
ET-02, a new hairloss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hairfollicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
PP405 is a new hairloss treatment targeting dormant hairfollicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
Sugary beverages increase the risk of pattern hairloss in men by 57%, and type 2 diabetes is linked to female pattern hairloss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hairloss.